Table 2.
Patient characteristics at inclusion (N=39).
| Characteristics | Values | ||
| Demographics | |||
|
|
Sex, n (%) | ||
|
|
|
Men | 24 (61) |
|
|
|
Women | 15 (39) |
| Age (years), mean (SD), range | 63.2 (9.2), 44.0-88.0 | ||
|
|
Highest education, n (%) | ||
|
|
|
Compulsory or less | 6 (16) |
|
|
|
Vocational training | 16 (42) |
|
|
|
High school diploma | 9 (24) |
|
|
|
University diploma | 6 (16) |
|
|
|
Other | 1 (3) |
|
|
|
Missing | 1 (3) |
| Treatment characteristics | |||
|
|
Line of treatment, n (%) | ||
|
|
|
1st line | 20 (51) |
|
|
|
2nd line | 6 (51) |
|
|
|
3rd line | 9 (23) |
|
|
|
4th or higher line | 4 (10) |
|
|
Duration of disease in days (median, IQR) | 1534 (695-2968) | |
|
|
Risk status risk (cytogenetics, or disease stage), n (%) | ||
|
|
|
High risk | 15 (38) |
|
|
|
Low risk | 24 (62) |
|
|
ECOGa status, n (%) | ||
|
|
|
0 | 15 (38) |
|
|
|
1 | 19 (49) |
|
|
|
2 | 5 (13) |
|
|
Primary systemic therapy regimen during the studyb, n (%) | ||
|
|
|
R mono (Lenalidomide) | 13 (33) |
|
|
|
KRd (Carfilzomib - Lenalidomide - Dexamethasone) | 7 (18) |
|
|
|
PdD (Pomalidomide - Dexamethason - Daratumumab) | 4 (10) |
|
|
|
KDd (Carfilzomib - Daratumumab - Dexamethasone) | 4 (10) |
|
|
|
Dd (Daratumumab - Dexamethasone) | 4 (10) |
|
|
|
VRd (Bortezomib - Lenalidomide - Dexamethasone) | 2 (5) |
|
|
|
PdE (Pomalidomide - Dexamethasone - Elotuzumab) | 1 (3) |
|
|
|
RDd (Lenalidomide - Daratumumab - Dexamethasone) | 1 (3) |
|
|
|
Vd (Bortezomib - Dexamethasone) | 2 (5) |
aECOG: Eastern Cooperative Oncology Group.
bMultiple therapies possible if patients switched therapies. Missing data not included in the calculation of percentages.